Low vasopressin in ME/CFS
One of the most frustrating patterns in managing ME/CFS and related dysautonomia conditions is fluid loading failure. Patients are advised to drink more water, increase sodium intake, and expand circulating volume. Some improve. Many do not. For the patients who don't, the clinical explanation is usually absent — "your volume is fine, keep trying." A 2025 paper by Huhmar in Endocrine Practice offers a specific hormonal mechanism that may explain why volume loading fails in a meaningful subset of patients: vasopressin signaling — the hormone that tells the kidneys to retain fluid and blood vessels to constrict — is underactive relative to what the body's physiological state should be triggering. The problem isn't that not enough fluid is being consumed. The problem is that the body isn't being told to keep it.
What Vasopressin Does and Why It Matters for Fluid Balance
Vasopressin, also called antidiuretic hormone (ADH), is produced in the hypothalamus and released by the posterior pituitary gland. Its job is to respond to two physiological signals: rising plasma osmolality (the blood is becoming more concentrated, which means the body needs to retain water to dilute it) and falling blood volume or blood pressure (the body is running low on circulating fluid and needs to retain more). When either of these signals reaches threshold, the hypothalamus increases vasopressin release, the kidneys respond by reabsorbing water back into the bloodstream instead of excreting it in urine, and blood vessels constrict to support blood pressure.
Vasopressin is the primary hormonal guardian of fluid balance. Without adequate vasopressin response, the body loses water that it should be retaining — producing a state of relative dehydration and volume depletion even when fluid intake is normal or elevated. The clinical presentation resembles chronic low blood volume: fatigue, orthostatic symptoms, difficulty maintaining blood pressure on standing, and poor response to fluid loading strategies that would be effective in people with intact vasopressin signaling.
The Finding: Blunted Vasopressin in ME/CFS
Huhmar's paper documents that a subset of ME/CFS patients show vasopressin levels that are insufficient relative to what their physiological state should be demanding. When plasma osmolality and blood volume indicators would normally trigger robust vasopressin release — the conditions are present, the signal should fire — the response is blunted. The hormone is not being released at the level the physiological situation calls for.
This is a central regulation problem. The hypothalamus, which monitors osmolality and volume signals through specialized neurons and decides when to release vasopressin, is not calibrating its response accurately. This is not a kidney failure problem — the kidneys can respond normally to vasopressin when it arrives. It is a signaling failure upstream: the central nervous system is underestimating the demand for fluid retention and not activating the retention response at the appropriate threshold.
The practical consequence is that fluid loading — drinking extra water, increasing sodium — produces temporary improvement at best. The body takes in the additional fluid, the plasma volume transiently expands, and then the kidneys excrete what the vasopressin signal is not instructing them to keep. The patient urinates out what they drank. This pattern — high fluid intake, high urine output, persistent low volume symptoms — is familiar to many ME/CFS patients and is often attributed to "not drinking enough." The Huhmar data suggest it may instead reflect inadequate hormonal instruction to retain what is being consumed.
The Connection to POTS and the RAAS Paradox
The vasopressin finding in ME/CFS parallels the renin-angiotensin-aldosterone system dysfunction documented in POTS. Raj and colleagues established that POTS patients have a 13% blood volume deficit despite the fact that their renin-aldosterone axis shows paradoxically low renin levels — the hormonal system that should be activated by low blood volume is underresponding relative to the circulatory state it is operating in. The result is the same: the body is carrying insufficient circulating volume, the hormonal system that should be correcting this is not fully activating, and adding fluid peripherally does not adequately resolve the deficit because the signaling infrastructure to retain it remains suboptimal.
Vasopressin is a separate axis from renin-aldosterone, but it addresses the same core problem from a different angle. Renin-aldosterone governs sodium and volume retention primarily through aldosterone's action on the kidney tubules. Vasopressin governs water retention through aquaporin channels in the collecting ducts. Both systems are part of the body's volume homeostasis architecture, and both appear to show signs of underactivation in ME/CFS and related conditions relative to the physiological state they are operating in.
This convergence of neuroendocrine dysregulation across multiple fluid-regulatory axes — both renin-aldosterone and vasopressin — points toward the hypothalamus as a site of dysregulation upstream of both. The hypothalamus integrates signals from baroreceptors, osmoreceptors, and circulating hormones to calibrate vasopressin release. The paraventricular and supraoptic nuclei of the hypothalamus are the same regions where autonomic regulation originates. Dysregulation in this region could simultaneously produce impaired vasopressin signaling, abnormal baroreflex function, and the elevated resting sympathetic tone documented in ME/CFS autonomic studies.
Why the Central Regulation Hypothesis Changes the Treatment Target
If vasopressin underactivation is a central neuroendocrine dysregulation rather than a peripheral fluid problem, the treatment target is different from what standard volume loading addresses. Fluid loading without supporting hormonal retention is a leaky bucket strategy — the intervention cannot be sustained because the system that would maintain the benefit is not functioning adequately.
Therapeutic approaches that target vasopressin directly — such as desmopressin, a synthetic vasopressin analogue used in diabetes insipidus and some dysautonomia protocols — would be logical candidates to test in this subgroup. Desmopressin acts on the V2 renal receptors to promote water retention and has been used experimentally in POTS management for its volume-expanding effects. In patients with blunted intrinsic vasopressin response, it could potentially address the retention failure that makes fluid loading ineffective.
This is a 2025 paper, and the clinical translation is not yet established. But the finding matters because it provides a mechanistic explanation for a clinical frustration — fluid loading failure in ME/CFS — that has previously had no specific biological anchor. The patients who drink large amounts of fluid and continue to show low-volume symptoms are not imagining their symptoms and are not failing to try hard enough with their fluid intake. They may have an underlying hormonal signaling problem that standard advice to "drink more water" cannot reach.
What This Means for Evaluating Volume Problems in ME/CFS
Standard evaluation of blood volume problems in ME/CFS and dysautonomia does not routinely include vasopressin measurement. The assessment typically covers basic electrolytes, sometimes renin and aldosterone levels, and clinical assessment of fluid intake and urine output. Vasopressin is a specialist measurement, generally ordered in the context of diabetes insipidus evaluation rather than dysautonomia workup.
The Huhmar paper raises the question of whether vasopressin measurement should be considered in ME/CFS patients who show persistent volume-related symptoms despite adequate fluid intake — particularly those who report high urine output, persistent thirst, or inability to sustain the benefits of fluid loading. Identifying which patients have blunted vasopressin response would distinguish those with a hormonal signaling problem from those with other volume-maintenance failures, and would point toward targeted intervention rather than continued escalation of strategies that are not addressing the relevant mechanism.
The emerging picture of ME/CFS neuroendocrine physiology — low vasopressin, paradoxically low renin despite volume deficit, elevated resting sympathetic tone, impaired baroreflex calibration — points consistently toward the hypothalamus and central autonomic regulatory centers as sites where the condition's physiology is organized. The peripheral symptoms: orthostatic intolerance, exercise limitation, fluid imbalance — are the output of a central regulatory system that is not accurately reading physiological state or producing appropriate corrective responses. Treating the periphery without addressing the central dysregulation is addressing consequences rather than causes.